BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
17.51
-0.58 (-3.21%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close18.09
Open0.00
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume979,684
Market Cap65.169B
Beta (3Y Monthly)1.29
PE Ratio (TTM)9.50
EPS (TTM)1.844
Earnings DateN/A
Forward Dividend & Yield0.81 (4.49%)
Ex-Dividend Date2018-05-25
1y Target Est32.23
Trade prices are not sourced from all markets
  • Bayer CEO says has not had contact with activist investor Elliott
    Reuters15 hours ago

    Bayer CEO says has not had contact with activist investor Elliott

    Bayer Chief Executive Werner Baumann said on Monday he has not had any contact with Elliott Management, following a Reuters report which said the U.S.-based activist investor had taken a position in the ...

  • Reuters15 hours ago

    Bayer CEO says has not had contact with activist investor Elliott

    DUESSELDORF (Reuters) - Bayer (BAYGn.DE) Chief Executive Werner Baumann said on Monday he has not had any contact with Elliott Management, following a Reuters report which said the U.S.-based activist ...

  • Reuters3 days ago

    Exclusive: Activist investor Elliott has stake in Germany's Bayer - sources

    FRANKFURT/NEW YORK (Reuters) - Activist investor Elliott has taken a position in Germany's Bayer, adding to the slew of investments the fund has made in German companies, three people familiar with the matter told Reuters on Friday. Elliott has held shares in Bayer for more than a year, two of the sources said, declining to specify the size of the stake. While Elliott has tried to talk to Bayer's top management it has not been able to get a meeting with Chief Executive Werner Baumann or his colleagues, one of the sources said, adding that Baumann also declined to talk to other hedge funds invested in the company.

  • Singer's Elliott Builds Bayer Stake in Breakup Push
    Bloomberg4 days ago

    Singer's Elliott Builds Bayer Stake in Breakup Push

    The activist investment firm wants the company’s management and board to evaluate breaking Bayer into separate pharmaceutical and agrochemical makers, the people said, asking not to be identified because the information is private. No meetings between Elliott and Bayer have yet taken place, the people said. Elliott has held shares in Bayer for more than a year, the people said.

  • Exclusive: Activist investor Elliott has stake in Germany's Bayer - sources
    Reuters4 days ago

    Exclusive: Activist investor Elliott has stake in Germany's Bayer - sources

    FRANKFURT/NEW YORK (Reuters) - Activist investor Elliott has taken a position in Germany's Bayer (BAYGn.DE), adding to the slew of investments the fund has made in German companies, three people familiar with the matter told Reuters on Friday. Elliott has held shares in Bayer for more than a year, two of the sources said, declining to specify the size of the stake. While Elliott has tried to talk to Bayer's top management it has not been able to get a meeting with Chief Executive Werner Baumann or his colleagues, one of the sources said, adding that Baumann also declined to talk to other hedge funds invested in the company.

  • Reuters4 days ago

    Bayer's German workers mostly spared from Monsanto-related job cuts - labour boss

    The lion's share of job cuts from folding U.S. seed maker Monsanto into Bayer's (BAYGn.DE) agriculture unit will affect workers outside Germany, the head of Bayer's works council told Reuters. "It's wrong to say that the employees now have to carry the can," Oliver Zuehlke, who represents Bayer's German workers, told Reuters.

  • Bayer's German workers mostly spared from Monsanto-related job cuts: labor boss
    Reuters4 days ago

    Bayer's German workers mostly spared from Monsanto-related job cuts: labor boss

    The lion's share of job cuts from folding U.S. seed maker Monsanto into Bayer's (BAYGn.DE) agriculture unit will affect workers outside Germany, the head of Bayer's works council told Reuters. "It's wrong to say that the employees now have to carry the can," Oliver Zuehlke, who represents Bayer's German workers, told Reuters.

  • Financial Times4 days ago

    [$$] Activist investor Elliott builds stake in Germany’s Bayer

    , in a move that could raise pressure on management to step up disposals or even push for a split of the sprawling chemicals and pharmaceuticals group. The size of the Elliott stake was unclear, but is certain to be below 3 per cent, the threshold at which German law requires disclosure. Elliott, Paul Singer’s $35bn activist investing firm, has a reputation for pursuing aggressive campaigns to shake up large companies and has experience operating in almost all of the world’s major markets including Germany.

  • Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx
    Zacks5 days ago

    Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx

    Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.

  • The Wall Street Journal5 days ago

    [$$] Bayer Lays Out Plans in Hopes of Easing Investor Headaches

    BERLIN—Germany’s Bayer AG Wednesday laid out ambitious sales and profit targets in its latest effort to convince the market it is serious about boosting profits, reducing debt and stopping a downward spiral in its stock price that has put management under heavy pressure. The chemicals and pharmaceuticals company is dealing with a string of long-term challenges and the fallout from its recent acquisition of Monsanto Co., a deal that was designed to strengthen Bayer’s strategic position but ended up spooking investors. “We are not happy at all with the recent development of the company and the stock,” Chief Executive Werner Baumann said in London at the company’s first gathering with investors since taking over Monsanto this summer.

  • Morningstar6 days ago

    Trimming Bayer's Fair Value on Restructuring Costs

    While we believe the restructuring makes strategic sense, the related one-time costs are higher than we expected.

  • Reuters6 days ago

    Lower drug sales potential at Bayer underscores need for deals

    Germany's Bayer (BAYGn.DE), which acquired seed company Monsanto this year, reduced its combined sales estimate for its most promising experimental drugs, acknowledging it needs to do more to replenish the development pipeline. At its capital markets day in London on Wednesday, it said the tally of peak sales potential of its five most promising drugs was more than 3.75 billion euros (3.34 billion pounds), compared with a target of more than 6 billion euros for the top six drugs reiterated as recently as June. Bayer last week announced the sale of a number of businesses, around 12,000 job cuts and 3.3 billion euros in impairments.

  • Lower drug sales potential at Bayer underscores need for deals
    Reuters6 days ago

    Lower drug sales potential at Bayer underscores need for deals

    Germany's Bayer (BAYGn.DE), which acquired seed company Monsanto this year, reduced its combined sales estimate for its most promising experimental drugs, acknowledging it needs to do more to replenish the development pipeline. At its capital markets day in London on Wednesday, it said the tally of peak sales potential of its five most promising drugs was more than 3.75 billion euros ($4.3 billion), compared with a target of more than 6 billion euros for the top six drugs reiterated as recently as June. Bayer last week announced the sale of a number of businesses, around 12,000 job cuts and 3.3 billion euros in impairments.

  • The Wall Street Journal6 days ago

    [$$] Bayer Sets New Growth Targets

    AG (BAYN.XE) said Wednesday that it is aiming to increase sales and profitability across all its divisions through 2022. Bayer last week said it would cut 12,000 jobs and sell its animal-health business, Coppertone and Dr. Scholl’s operations, as the company faces challenges in many businesses and thousands of lawsuits related to weedkillers it recently acquired as part of Monsanto. Between 2019 and 2022, Bayer said it targets free cash flow of about EUR23 billion.

  • 10 Defensive Stocks to Protect Your Portfolio in 2019
    InvestorPlace7 days ago

    10 Defensive Stocks to Protect Your Portfolio in 2019

    Following the highly anticipated sit-down between President Donald Trump and Chinese President Xi Jinping at the G-20 summit, investors received a respite: the White House says both leaders agreed to temporarily halt escalating sanctions. Trump has never enjoyed a reputation as a steady, calm hand in the face of stress or provocation. While the agreement facilitates a 90-day ceasefire regarding the ongoing trade war, investors should adopt a measured approach.

  • Benzinga8 days ago

    Bayer To Cut 12,000 Jobs Following Monsanto Purchase

    Earlier this year, German pharmaceutical company Bayer AG (OTC: BAYRY) announced its $60-million acquisition of Monsanto. Bayer will cut roughly 12,000 jobs globally by the end of 2021, according to CNN Business. Bayer’s cost restructuring should reduce negative pressure and allow the company to focus on its core business.

  • The Wall Street Journal11 days ago

    [$$] Asset Sales, Cost Cuts Challenge Bayer CFO

    as the drugs and chemicals giant battles a decline in investor confidence following its acquisition of Monsanto Co. Leverkusen, Germany-based Bayer on Thursday announced it would cut 12,000 jobs—around 10% of its 118,200 strong global workforce—and dispose of its animal-health business, some consumer brands and a 60% stake in chemical park operator Currenta. Mr. Nickl—who took on the role of Chief Financial Officer on June 1 after a stint as CFO of ASML NV, a Dutch supplier of machines for making computer chips—will be involved with executing the program and delivering synergies from the Monsanto transaction, according to analysts.

  • Bayer (BAYRY) to Restructure Business & Reduce Headcount
    Zacks11 days ago

    Bayer (BAYRY) to Restructure Business & Reduce Headcount

    Bayer (BAYRY) conducts a strategic review of its business model, and plans to exit unprofitable product lines and reduce headcount.

  • The Wall Street Journal11 days ago

    [$$] Bayer to Cut 12,000 Jobs, Shed Coppertone and Dr. Scholl’s Brands

    BERLIN—Bayer AG on Thursday said it would cut 12,000 jobs and sell its animal-health business, Coppertone sunscreens and Dr. Scholl’s foot-care products in an effort to win back investors’ trust after a string of setbacks and a sharp fall in its share price. The job cuts, targeting some 10% of Bayer’s 118,200 global workforce, come as the German chemicals and pharmaceuticals company faces challenges in most of its businesses, from falling sales of over-the-counter drugs to a dwindling stable of blockbuster prescription medicines. Compounding its difficulties, the company known mainly as the inventor of Aspirin faces nearly 10,000 lawsuits from users of weedkillers it recently acquired as part of Monsanto.

  • Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma
    Investor's Business Daily12 days ago

    Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma

    Bayer announced Thursday it will cut 12,000 jobs amid a strategic overhaul to focus on its pharmaceuticals, consumer health and crop science businesses.

  • Reuters12 days ago

    Bayer sees more than 4 billion euro in one-off costs from restructuring

    FRANKFURT (Reuters) - Bayer (BAYGn.DE) said it will incur one-off costs in excess of 4 billion euros (3.60 billion pounds) as a result of the job-cutting programme it unveiled on Thursday. "We aim ...

  • German pharmaceutical company Bayer cutting 12,000 jobs
    Associated Press12 days ago

    German pharmaceutical company Bayer cutting 12,000 jobs

    BERLIN (AP) — German pharmaceutical giant Bayer AG says it's cutting 12,000 jobs worldwide as it seeks to reduce costs.

  • Benzinga14 days ago

    Raymond James Sees $1B Potential In Loxo Oncology's Vitrakvi, LOXO-95

    The FDA announced approval Monday of Loxo Oncology Inc (NASDAQ: LOXO ) and  Bayer AG (OTC: BAYRY ) Vitrakvi — chemically larotrectinib — for adults and pediatric patients with advanced or metastatic solid ...

  • Bayer's TRK Inhibitor Gets FDA Nod for Advanced Solid Tumors
    Zacks14 days ago

    Bayer's TRK Inhibitor Gets FDA Nod for Advanced Solid Tumors

    Bayer (BAYRY) receives the FDA approval for larotrectinib for the treatment of adult and pediatric patients having solid tumors with NTRK gene fusion.

  • Reuters14 days ago

    Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

    A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday. The drug, larotrectinib, will be sold under the brand name Vitrakvi and priced at $32,800 per month, in partnership with Bayer AG. Kevin O'Leary, Bayer's vice president of pricing and contracting, said Bayer and Loxo will assist patients financially and offer a value-based program, refunding both out-of-pocket and insurer payments for patients who do not see a clinical benefit within the first three months of treatment.